8-K
filed May 5, 2025, 7:59 PM ET
CIK 0001463361
other material
confidence high
sentiment negative
materiality 1.00
Unity Biotechnology, Inc.: restructuring charge — Unity Biotech lays off all employees, explores strategic alternatives after Phase 2b miss
Unity Biotechnology, Inc.
- Company reducing entire workforce; expects $3.7M in severance and related cash costs; completion by May 15, 2025.
- CEO Anirvan Ghosh, CFO Lynne Sullivan, and Chief Legal Officer Alexander Nguyen will terminate employment May 15, transition to advisory consulting roles.
- Phase 2b ASPIRE study of UBX1325 in DME showed non-inferiority to aflibercept at week 36 but missed primary endpoint at average of weeks 20 and 24.
- Strategic alternatives include sale, license, monetization, merger, or wind-down of the company; no assurance of any transaction.
- Cash and equivalents $16.9M as of March 31, 2025; company reducing operational cash burn.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Anirvan Ghosh departed as Chief Executive Officer at Unity Biotechnology, Inc..
- Action
- terminated employment
- Role
- Chief Executive Officer
Exact text from the filing
each of Anirvan Ghosh, Lynne Sullivan, and Alexander Nguyen, the Company’s Chief Executive Officer, Chief Financial Officer and Head of Corporate Development, and Chief Legal Officer and Head of Operations, respectively, will terminate employment with the Company, effective May 15, 2025
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Lynne Sullivan departed as Chief Financial Officer and Head of Corporate Development at Unity Biotechnology, Inc..
- Action
- terminated employment
- Role
- Chief Financial Officer and Head of Corporate Development
Exact text from the filing
each of Anirvan Ghosh, Lynne Sullivan, and Alexander Nguyen, the Company’s Chief Executive Officer, Chief Financial Officer and Head of Corporate Development, and Chief Legal Officer and Head of Operations, respectively, will terminate employment with the Company, effective May 15, 2025
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Alexander Nguyen departed as Chief Legal Officer and Head of Operations at Unity Biotechnology, Inc..
- Action
- terminated employment
- Role
- Chief Legal Officer and Head of Operations
Exact text from the filing
each of Anirvan Ghosh, Lynne Sullivan, and Alexander Nguyen, the Company’s Chief Executive Officer, Chief Financial Officer and Head of Corporate Development, and Chief Legal Officer and Head of Operations, respectively, will terminate employment with the Company, effective May 15, 2025
View on SEC.gov
Restructurings & Charges
SEC 8-K Item 2.05/2.06
confidence 0.9
Unity Biotechnology, Inc. announced a restructuring with charges of approximately $3.7 million (a reduction in force affecting all of its employees).
- Type
- restructuring
- Charge
- approximately $3.7 million
- Headcount
- a reduction in force affecting all of its employees
Exact text from the filing
The Company estimates that it will incur aggregate cash expenses of approximately $3.7 million in connection with the reduction in force, including severance, benefits, and related termination costs, which includes fees to be paid under consulting agreements.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.